Medicare cuts push Orthofix (NASDAQ: OFIX) to lower 2026 outlook and scrap 3-year goals
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Orthofix Medical Inc. is updating its outlook after Medicare reimbursement changes for non-invasive bone growth stimulators. Following an FDA reclassification of these devices to Class II and related CMS billing updates effective May 18, 2026, the company expects average Medicare reimbursement for key HCPCS codes to decline by about 10%.
Orthofix now projects full-year 2026 net sales of $838–$848 million and non-GAAP adjusted EBITDA of $90–$93 million, and it does not expect positive free cash flow for 2026. The company has withdrawn its three-year financial targets and will continue assessing the long-term effects of current and future CMS actions.
Positive
- None.
Negative
- Medicare reimbursement pressure: Orthofix expects average Medicare reimbursement for key non-invasive bone growth stimulator codes to decline by about 10%, directly impacting revenue and margins.
- Weaker 2026 outlook and cash flow: New guidance of $838–$848 million in 2026 net sales and $90–$93 million in non-GAAP adjusted EBITDA is paired with an expectation of no positive free cash flow for 2026.
- Withdrawal of long-term targets: The company’s three-year financial targets are no longer applicable, signaling increased uncertainty around longer-term performance due to CMS reimbursement actions.
Insights
CMS reimbursement cuts drive a weaker 2026 outlook and withdrawn long-term targets.
Orthofix highlights a roughly 10% drop in average Medicare reimbursement for non-invasive bone growth stimulators, tied to FDA reclassification and CMS billing and fee schedule changes effective May 18, 2026. This directly pressures revenue and profitability in a key product area.
The company now guides to $838–$848M in 2026 net sales and $90–$93M in non-GAAP adjusted EBITDA, and no longer expects positive free cash flow for the year. Management has also withdrawn its three-year financial targets, underscoring uncertainty around the longer-term impact of reimbursement changes. Future CMS decisions and resulting claim volumes and payer behavior will be important for understanding sustained effects, based on upcoming company disclosures.
8-K Event Classification
Item 7.01 — Regulation FD Disclosure
1 item
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Key Figures
Medicare reimbursement change: ≈10% decline
2026 net sales guidance: $838–$848 million
2026 non-GAAP adjusted EBITDA: $90–$93 million
+3 more
6 metrics
Medicare reimbursement change
≈10% decline
Average Medicare reimbursement for HCPCS E0747, E0748, E0760
2026 net sales guidance
$838–$848 million
Full-year 2026 expected net sales
2026 non-GAAP adjusted EBITDA
$90–$93 million
Full-year 2026 non-GAAP adjusted EBITDA guidance
2026 free cash flow
Not expected to be positive
Full-year 2026 free cash flow outlook
FDA device reclassification
Class III to Class II
Non-invasive bone growth stimulators reclassified on April 16, 2026
Effective date for CMS changes
May 18, 2026
Dates of service for updated billing and fee schedule
Key Terms
non-invasive bone growth stimulators, HCPCS codes, non-GAAP adjusted EBITDA, free cash flow, +2 more
6 terms
non-invasive bone growth stimulators medical
"reclassifying non-invasive bone growth stimulators from Class III to Class II devices"
HCPCS codes technical
"billed under HCPCS codes E0747, E0748 and E0760 for dates of service"
non-GAAP adjusted EBITDA financial
"expects net sales for full-year 2026 to be in the range of $838 million to $848 million and non-GAAP adjusted EBITDA"
Non-GAAP adjusted EBITDA is a measure of a company's profitability that shows earnings before interest, taxes, depreciation, and amortization, with certain adjustments made to exclude irregular or non-recurring expenses and income. It provides a clearer picture of ongoing operational performance by filtering out items that might distort the core business results. Investors use it to better compare how well different companies are performing without the noise of one-time events.
free cash flow financial
"At this time, the Company does not expect positive free cash flow for full-year 2026."
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure."
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
forward-looking statements regulatory
"This disclosure contains forward-looking statements within the meaning of Section 21E"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
How are CMS reimbursement changes affecting Orthofix Medical (OFIX)?
CMS billing and fee schedule updates for non-invasive bone growth stimulators are expected to reduce Orthofix’s average Medicare reimbursement by about 10%. This change pressures revenue and profitability in that product category beginning with dates of service on or after May 18, 2026.
What 2026 net sales guidance did Orthofix Medical (OFIX) provide?
Orthofix now expects 2026 net sales between $838 million and $848 million. This range reflects the anticipated impact of lower Medicare reimbursement for certain non-invasive bone growth stimulators following recent FDA reclassification and CMS billing and payment changes.
What is Orthofix Medical’s 2026 non-GAAP adjusted EBITDA outlook?
The company projects 2026 non-GAAP adjusted EBITDA of $90 million to $93 million. This guidance incorporates the expected reimbursement-driven revenue impact on its non-invasive bone growth stimulators and reflects current assumptions about operating costs and business performance.
Does Orthofix Medical (OFIX) expect positive free cash flow in 2026?
No. Orthofix explicitly states it does not expect positive free cash flow for full-year 2026. This outlook is tied to the financial impact of reduced Medicare reimbursement and the company’s current assumptions about operating performance and capital needs during the year.
What happened to Orthofix Medical’s three-year financial targets?
Orthofix states that its three-year financial targets are no longer applicable. This change reflects uncertainty around the longer-term impact of current and potential future CMS reimbursement actions on its non-invasive bone growth stimulator business and overall financial performance.
When do the new Medicare billing changes start affecting Orthofix Medical?
The billing and Medicare fee schedule changes for non-invasive bone growth stimulators apply to services billed under HCPCS codes E0747, E0748 and E0760 for dates of service on or after May 18, 2026. Orthofix’s updated 2026 outlook incorporates these effective dates.